BioCentury | Dec 11, 2017
Preclinical News

Histone modifier is implicated in epithelial-mesenchymal transition

...them will prevent further tumor proliferation and metastasis. At least 13 companies are developing cancer stem cell therapeutics...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
BioCentury | Jan 28, 2016
Strategy

CIRM's endgame

...the document, CIRM also outlines its bleak assessment of the regulatory environment for development of stem cell therapeutics.CIRM...
BioCentury | Jan 18, 2016
Clinical News

Mesenchymal precursor cells: Phase III amended

...about 600 using the same primary endpoint. Mesoblast and Teva partnered to develop and commercialize stem cell therapeutics...
BioCentury | Apr 28, 2014
Financial News

Stem Cell Therapeutics financial update

...listing to the Toronto Stock Exchange under the symbol "SSS" from the Toronto Stock Exchange-Venture. Stem Cell Therapeutics Corp....
BioCentury | Feb 3, 2014
Company News

Stem Cell Therapeutics board of directors update

Stem Cell Therapeutics Corp. (TSX-V:SSS; OTCQX:SCTPF), Toronto, Ontario Business: Gene/Cell therapy Appointed: Calvin Stiller, a director, as chairman WIR Staff...
BioCentury | Dec 23, 2013
Financial News

Stem Cell Therapeutics completes private placement of units

Stem Cell Therapeutics Corp. (TSX-V:SSS; OTCQX:SCTPF), Toronto, Ontario Business: Gene/Cell therapy Date completed: 12/13/13 Type: Private placement of units Raised: C$33 million ($31.2 million) Units: 157.1 million Price: C$0.21 (unit) Shares after offering: 121.8 million...
BioCentury | Dec 17, 2013
Financial News

Stem Cell Therapeutics raises $31.2 million

...each whole warrant exercisable at C$0.28. Bloom Burton and Roth Capital Partners were placement agents. Stem Cell Therapeutics'...
BioCentury | Nov 11, 2013
Clinical News

Mesenchymal precursor cells: Phase III start

...about 1,700 patients with chronic CHF. Mesoblast is partnered with Teva to develop and commercialize stem cell therapeutics...
BioCentury | Nov 11, 2013
Clinical News

Tigecycline regulatory update

...glycylcycline antibiotic is in a Phase I trial in patients with relapsed or refractory AML. Stem Cell Therapeutics...
...skin and skin structure infections (cSSSI), complicated intra-abdominal infections (cIAI) and community-acquired bacterial pneumonia (CABP). Stem Cell Therapeutics Corp....
Items per page:
1 - 10 of 92
BioCentury | Dec 11, 2017
Preclinical News

Histone modifier is implicated in epithelial-mesenchymal transition

...them will prevent further tumor proliferation and metastasis. At least 13 companies are developing cancer stem cell therapeutics...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
BioCentury | Jan 28, 2016
Strategy

CIRM's endgame

...the document, CIRM also outlines its bleak assessment of the regulatory environment for development of stem cell therapeutics.CIRM...
BioCentury | Jan 18, 2016
Clinical News

Mesenchymal precursor cells: Phase III amended

...about 600 using the same primary endpoint. Mesoblast and Teva partnered to develop and commercialize stem cell therapeutics...
BioCentury | Apr 28, 2014
Financial News

Stem Cell Therapeutics financial update

...listing to the Toronto Stock Exchange under the symbol "SSS" from the Toronto Stock Exchange-Venture. Stem Cell Therapeutics Corp....
BioCentury | Feb 3, 2014
Company News

Stem Cell Therapeutics board of directors update

Stem Cell Therapeutics Corp. (TSX-V:SSS; OTCQX:SCTPF), Toronto, Ontario Business: Gene/Cell therapy Appointed: Calvin Stiller, a director, as chairman WIR Staff...
BioCentury | Dec 23, 2013
Financial News

Stem Cell Therapeutics completes private placement of units

Stem Cell Therapeutics Corp. (TSX-V:SSS; OTCQX:SCTPF), Toronto, Ontario Business: Gene/Cell therapy Date completed: 12/13/13 Type: Private placement of units Raised: C$33 million ($31.2 million) Units: 157.1 million Price: C$0.21 (unit) Shares after offering: 121.8 million...
BioCentury | Dec 17, 2013
Financial News

Stem Cell Therapeutics raises $31.2 million

...each whole warrant exercisable at C$0.28. Bloom Burton and Roth Capital Partners were placement agents. Stem Cell Therapeutics'...
BioCentury | Nov 11, 2013
Clinical News

Mesenchymal precursor cells: Phase III start

...about 1,700 patients with chronic CHF. Mesoblast is partnered with Teva to develop and commercialize stem cell therapeutics...
BioCentury | Nov 11, 2013
Clinical News

Tigecycline regulatory update

...glycylcycline antibiotic is in a Phase I trial in patients with relapsed or refractory AML. Stem Cell Therapeutics...
...skin and skin structure infections (cSSSI), complicated intra-abdominal infections (cIAI) and community-acquired bacterial pneumonia (CABP). Stem Cell Therapeutics Corp....
Items per page:
1 - 10 of 92